Treatment of intrahepatic cholangiocarcinoma (iCCA) is currently at a significant turning point due to the identification of isocitrate dehydrogenase (IDH) mutations and fibroblast growth factor receptor (FGFR) fusions that can be targeted with currently available therapies. Clinical trials of these targeted therapies have been promising, and the iCCA patients who may benefit from these targeted treatments can be identified by pathological examination prior to molecular investigations. This is because IDH mutations and FGFR fusions are mainly seen in the small duct type iCCA, a subtype of iCCA defined by the 5th World Health Organization classification, which can be recognized by the pathological diagnostic process. Therefore, pathology plays an important role in precision medicine for iCCA, not only in confirming the diagnosis, but also in identifying the iCCA patients who may benefit from targeted treatments. However, caution is advised with the pathological diagnosis, as iCCA shows tumour heterogeneity, making it difficult to distinguish small duct type iCCA from hepatocellular carcinoma (HCC), and combined HCC-CCA. This review focuses on the pathological/molecular features of both subtypes of iCCA (large and small duct types), as well as their diagnostic pitfalls, clinical relevance, and future perspectives.
Citations
Citations to this article as recorded by
FXYD3 Promotes Tumor Progression by Binding With IRF7 to Regulate JAK2/STAT5 Signaling in Intrahepatic Cholangiocarcinoma Yan Zhou, Xiaofeng Shen, Shuo Zhang, XiaoHong Pu, Zipeng Xu, Xiang Zhao, Wei Feng, Yuan Liang, Xingtao He, Aihua Yang, Yudong Qiu, Yihang Yuan, Chaobo Chen, Jun Chen Advanced Science.2026;[Epub] CrossRef
Lactate metabolism-driven tumor heterogeneity and molecular signatures in intrahepatic cholangiocarcinoma An-Ke Wu, Jun-Yi Li, Kai Zhang, Martin Meng, Xue Wang, Yue Liu, Peng Xie, Wei-Qi Rong, Fan Wu, Hong-Guang Wang, Xuan Meng, Jian-Xiong Wu World Journal of Gastroenterology.2026;[Epub] CrossRef
Comprehensive molecular-clinical profiling of cholangiocarcinoma according to pathologic subtypes Keun Soo Ahn, Daniel O'Brien, Yoo Na Kang, Taofic Mounajjed, Hye Won Lee, Yong Hoon Kim, Tae-Seok Kim, Min Jae Kim, Jin-Yi Han, Mitesh J. Borad, Lewis R. Roberts HPB.2026; 28(6): 796. CrossRef
Efficacy and safety of immune checkpoint inhibitors in patients with high microsatellite instability/mismatch repair–deficient advanced cholangiocarcinoma: A propensity score–matched study Mingjian Piao, Xu Yang, Chengjie Li, Jiayi Zhao, Nan Zhang, Jiongyuan Li, Ziyue Huang, Shuofeng Li, Boyu Sun, Xiaobo Yang, Haitao Zhao JHEP Reports.2026; 8(5): 101816. CrossRef
Targeting MUC16 suppresses malignant progression and chemoresistance in large-duct type intrahepatic cholangiocarcinoma Chen Sang, Dongning Rao, Haokai Qin, Mao Zhang, Rongkui Luo, Yingying Huang, Jiaomeng Pan, Youpei Lin, Shu Zhang, Jian Lin, Qiang Gao Cancer Letters.2026; 646: 218434. CrossRef
Cholangiolocellular Component Predicts a Biologically Distinct Subgroup of Mass‐Forming Intrahepatic Cholangiocarcinoma Naoto Kubota, Ken Yamazaki, Yasuhito Arai, Minoru Esaki, Nobuyoshi Hiraoka, Hirofumi Shirakawa, Moriaki Tomikawa, Tatsuhiro Shibata, Michiie Sakamoto, Hidenori Ojima Cancer Science.2026; 117(5): 1510. CrossRef
Single-cell and bulk transcriptomic analyses uncover immune subtypes associated with programmed cell death features in intrahepatic cholangiocarcinoma Tiancai Zhang, Dongqing Dou, Qi Liu, Dong Xu, Tong Wang, Rong Liu, Danyang Lu, Xiaofang Zhao, Senyan Wang, Huapeng Zhang Scientific Reports.2026;[Epub] CrossRef
Gemcitabine-cisplatin plus durvalumab in advanced intrahepatic cholangiocarcinoma: effectiveness outcomes and characterization of the tumor microenvironment Jiawei Xu, Yifan Ji, Min Feng, Zhiheng Zhang, Decai Yu Hepatology International.2026;[Epub] CrossRef
From organelles to therapy: rethinking combined hepatocellular-cholangiocarcinoma Tiezhong Zhang, Kangshuai Li, Qi Li, Qiang Gao, Lixin Du, Jian Deng, Zhuohan Cao, Sen Guo, Zongli Zhang Frontiers in Cell and Developmental Biology.2026;[Epub] CrossRef
IGF2BP2 Overexpression Predicts Poor Prognosis and Correlates with PD-L1 Expression in Intrahepatic Cholangiocarcinoma Jianan Shen, Aihua Yang, Xintao He, Tianyi Dai, Zexuan Hui, Youxiang Ding, Li Zhao, Jun Chen Biomedicines.2026; 14(4): 929. CrossRef
Prognostic models for intrahepatic cholangiocarcinoma after resection: A systematic review and meta-analysis Yizhao Liu, Xia Lei, Jinyong Hao, Jihua Yang, Hanzhou Bao, Qiao Wang, Xiaojun Huang Clinics and Research in Hepatology and Gastroenterology.2026; 50(6): 102844. CrossRef
Surgical interpretation of the WHO subclassification of intrahepatic cholangiocarcinoma: a narrative review Masayuki Akita, Hiroaki Yanagimoto, Daisuke Tsugawa, Yoh Zen, Takumi Fukumoto Surgery Today.2025; 55(1): 1. CrossRef
Standardizing the reporting of cholangiocarcinoma: the society of abdominal radiology disease focused panel on cholangiocarinoma lexicon Robert M. Marks, Hina Arif, Maria Antonietta Bali, Ryan L. Brunsing, Guilherme M. Cunha, Hala Khasawneh, Maria El Homsi, Charanjeet Singh, Raj Paspulati, Andrea Kierans, Aliya Qayyum Abdominal Radiology.2025; 50(7): 2858. CrossRef
SQSTM1/p62 confers resistance of intrahepatic cholangiocarcinoma cells to 5-Fluorouracil by promoting Nrf2 nuclear translocation Xuanming Luo, Qinwen Tai, Xuan Liu, Xingni Zhou, Wenxiang Li, Houbao Liu, Zhenbin Ding, Miyesaier Abudureyimu Molecular & Cellular Toxicology.2025; 21(4): 917. CrossRef
Correspondence to editorial on “Development and validation of a stromal-immune signature to predict prognosis in intrahepatic cholangiocarcinoma” Yu-Hang Ye, Shao-Lai Zhou Clinical and Molecular Hepatology.2025; 31(1): e90. CrossRef
Conversion treatment for advanced intrahepatic cholangiocarcinoma: Opportunities and challenges Jun-Jie Liu, Mi Zhou, Tong Yuan, Zhi-Yong Huang, Zun-Yi Zhang World Journal of Gastroenterology.2025;[Epub] CrossRef
Contrast-enhanced ultrasound imaging characteristics of intrahepatic cholangiocarcinoma with actionable gene variants detected by comprehensive cancer gene panel testing Kazunori Nakaoka, Eizaburo Ohno, Seiji Yamada, Teiji Kuzuya, Tamotsu Sudo, Sayaka Ueno, Hiroyuki Tanaka, Yutaka Sasaki, Ryoji Miyahara, Senju Hashimoto, Yoshiki Hirooka International Journal of Clinical Oncology.2025; 30(7): 1398. CrossRef
Diagnosis and Treatment of Intrahepatic Cholangiocarcinoma Takamichi Ishii, Etsuro Hatano Kanzo.2025; 66(6): 213. CrossRef
Comparison of MRI and prognostic features of intrahepatic cholangiocarcinoma between patients with and without hepatitis B virus infection Se Jin Choi, Dong Hwan Kim, Sang Hyun Choi, So Yeon Kim, Seung Soo Lee, Jae Ho Byun, Hyung Jin Won, Yong Moon Shin Abdominal Radiology.2025; 50(12): 5820. CrossRef
Association between ultrasound-based biliary and parenchymal intrahepatic mass-forming cholangiocarcinoma subtypes and clinicopathological features and survival Cong-Jian Wen, Hui Liu, Li-Ping Sun, Chong-Ke Zhao, Hao-Hao Yin, Li-Fan Wang, Ming-Rui Zhu, Yi-Kang Sun, Ya-Qin Zhang, Zi-Tong Chen, Xi Wang, Han-Sheng Xia, Hong Han, Hui-Xiong Xu, Bo-Yang Zhou Insights into Imaging.2025;[Epub] CrossRef
Liver transplantation for intrahepatic cholangiocarcinoma: Insights from a National Registry Study in China Pengcheng Wei, Delin Ma, Chen Lo, Yongjing Luo, Jie Gao, Lei Huang, Jiye Zhu, Guangming Li, Shusen Zheng, Zhao Li Medicine.2025; 104(42): e44942. CrossRef
Exploratory study on the role of Clonorchis sinensis infection in promoting cholangiocarcinoma progression Shitao Li, Yiqi Jiang, Jun Kawanokuchi, Xueling Deng, Yuhong Wu, Yu Chen, Lixia Zeng, Ganghuan Deng, Damian Li, Tingzheng Zhan, Dengyu Liu, Ning Ma, Zeli Tang Parasites & Vectors.2025;[Epub] CrossRef
Preoperative Prediction of Microvascular Invasion in Intrahepatic Cholangiocarcinoma and Its Prognostic Implications: A Multicenter Study Hyeon Ji Jang, Dong Hwan Kim, Sang Hyun Choi, Hyungjin Rhee, Eun-Suk Cho, Suk-Keu Yeom, Sumi Park, Seung Soo Lee, Mi-Suk Park Liver Cancer.2025; 15(1): 63. CrossRef
Combined Hepatocellular-Cholangiocarcinoma: Biology, Diagnosis, and Management Liangtao Ye, Julia S. Schneider, Najib Ben Khaled, Peter Schirmacher, Carolin Seifert, Lea Frey, Yulong He, Andreas Geier, Enrico N. De Toni, Changhua Zhang, Florian P. Reiter Liver Cancer.2024; 13(1): 6. CrossRef
UBA3 promotes the occurrence and metastasis of intrahepatic cholangiocarcinoma through MAPK signaling pathway Huhu Zhang, Jiahua Yang, Qinghang Song, Xiaoyan Ding, Fulin Sun, Lina Yang Acta Biochimica et Biophysica Sinica.2024; 56(2): 199. CrossRef
Intrahepatic cholangiocarcinoma: histological diversity and the role of the pathologist Mina Komuta Journal of Liver Cancer.2024; 24(1): 17. CrossRef
Targeted therapies in advanced biliary malignancies: a clinical review Udhayvir S. Grewal, Shiva J. Gaddam, Muhammad S. Beg, Timothy J. Brown Expert Review of Anticancer Therapy.2024; 24(9): 869. CrossRef
Identification of molecular subtypes based on bile acid metabolism in cholangiocarcinoma Mingxia Deng, Jing Liu, Li Zhang, Yan Lou, Yunqing Qiu BMC Cancer.2024;[Epub] CrossRef
Integrative analysis of multiple genomic data from intrahepatic cholangiocarcinoma organoids enables tumor subtyping Hee Seung Lee, Dai Hoon Han, Kyungjoo Cho, Soo Been Park, Chanyang Kim, Galam Leem, Dawoon E. Jung, Soon Sung Kwon, Chul Hoon Kim, Jung Hyun Jo, Hye Won Lee, Si Young Song, Jun Yong Park Nature Communications.2023;[Epub] CrossRef
Establishment and characterization of a new intrahepatic cholangiocarcinoma cell line, ICC-X3 Hao Xu, Wei Luo, Zhenjie Zhao, Xin Miao, Changpeng Chai, Jinjing Hu, Huan Tang, Hui Zhang, Wence Zhou Human Cell.2023; 36(2): 854. CrossRef
A Case of Prostatic Metastasis from Intrahepatic Cholangiocarcinoma: An Extremely Rare Event Sanathan Aiyadurai, Tulika Garg, Tass Sayeed, Zainab Shahbaz, Idowu O Adewole, Enoh Nguty Nkeng, Abia Joseph, Datiobong Udoeyop, Yusra Qamar, Aadil Khan Cureus.2023;[Epub] CrossRef
Immune microenvironment of cholangiocarcinoma: Biological concepts and treatment strategies Xianzhe Yu, Lingling Zhu, Ting Wang, Jiang Chen Frontiers in Immunology.2023;[Epub] CrossRef
Clinicopathological, etiological and molecular characteristics of intrahepatic cholangiocarcinoma subtypes classified by mucin production and immunohistochemical features Yi Chen, Xiaoling Liu, Liyun Huang, Lihong Chen, Bin Wang Expert Review of Molecular Diagnostics.2023; 23(5): 445. CrossRef
Novel cell subtypes of SPP1 + S100P+, MS4A1-SPP1 + S100P+ were key subpopulations in intrahepatic cholangiocarcinoma Zixue Xuan, Linqing Liu, Guobing Zhang, Xiaowei Zheng, Jinying Jiang, Kai Wang, Ping Huang Biochimica et Biophysica Acta (BBA) - General Subjects.2023; 1867(9): 130420. CrossRef
Liver Transplantation for Incidental Cholangiocarcinoma or Combined Hepatocellular Carcinoma/Cholangiocarcinoma—Own Experiences and Review of the Literature Laura Schwenk, Oliver Rohland, Aladdin Ali-Deeb, Felix Dondorf, Utz Settmacher, Falk Rauchfuß Cancers.2023; 15(14): 3609. CrossRef
Beyond the Lab and Into the Hospital: An Outlook on the Clinical Utility of Spatial Omics Technologies Dean M. Pucciarelli, Benjamin Y. Lu, Inti Zlobec, Marcello DiStasio GEN Biotechnology.2023; 2(5): 360. CrossRef
Targeted mutation-based therapy for intrahepatic cholangiocarcinoma Facai Yang, Yinghe Qiu, Bin Yi Hepatoma Research.2023;[Epub] CrossRef
Clinical relevance of biomarkers in cholangiocarcinoma: critical revision and future directions Rocio I R Macias, Vincenzo Cardinale, Timothy J Kendall, Matias A Avila, Maria Guido, Cedric Coulouarn, Chiara Braconi, Adam E Frampton, John Bridgewater, Diletta Overi, Stephen P Pereira, Marco Rengo, Jakob N Kather, Angela Lamarca, Federica Pedica, Alej Gut.2022; 71(8): 1669. CrossRef
First
Prev
